News

Evidence of pleuroparenchymal fibroelastosis (PPFE) — a rare type of interstitial lung disease — in people with systemic sclerosis (SSc) carries a negative prognosis, a study shows. Therefore, SSc patients with PPFE should be closely monitored and receive regular follow-up by their healthcare team. The study, titled “…

Loss of muscle mass and strength — known as sarcopenia — may affect up to 55% of patients with systemic sclerosis (SSc), a study suggests. Moreover, sarcopenia was found to be associated with several clinical and nutritional parameters of disease severity. The study, “Sarcopenia in systemic sclerosis: the impact…

Levels of a pro-inflammatory signaling molecule, called interleukin (IL)-6, are significantly high in skin lesions and blood samples of patients with systemic sclerosis (SSc), especially among those with diffuse cutaneous SSc, a small Japanese study reports. The study, “IL-16 expression is increased in the skin and sera of…

Patients with scleroderma show more frequent and/or stronger immune responses against the human cytomegalovirus (HCMV), suggesting a role in disease development, according to new research. The findings also revealed a correlation between these viral responses and scleroderma-associated autoantibodies. The study, “A comprehensive analysis of antigen-specific antibody…

Systemic sclerosis (SSc) patients with elevated protein in their urine (proteinuria) who are using angiotensin-converting enzyme (ACE) inhibitors (ACEi) are at higher risk of developing scleroderma renal crisis (SRC), a retrospective study shows. The study, “Systemic sclerosis mediations and risk of scleroderma renal crisis,” was published in the…

Some people with systemic sclerosis (SSc) are protected from cancer development by the presence of anti-RNA polymerase I autoantibodies, a study suggests. The study, “Scleroderma patients with antibodies against the large subunits of both…

Screening newborns for genetic diseases with treatments that can prevent crippling or deadly progression, especially for rare disorders, has a ways to go in the United States. No state today tests for all 35 disorders recommended under a federal screening panel, and even in those that come close, rare…

Oklahoma suffers more tornadoes than any other state, has the highest per-capita rate of women in U.S. prisons, ranks second in the number of teen births per 100,000 teenage girls, and has the nation’s third-highest rate of uninsured residents — with 13.9% of all Oklahomans lacking health coverage. As if…

Abatacept, a potential treatment for people with early-stage diffuse cutaneous systemic sclerosis (dcSSc), showed clinically significant improvements in patients’ functional ability and overall health, despite failing to significantly reduce skin thickening, a Phase 2 study concluded.  The study, “Abatacept…

The Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) has recommended — via a 10-7 vote — the approval of Ofev (nintedanib) for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). Ofev, marketed by Boehringer Ingelheim, is…